Abstracts tagged "Nonsteroidal antiinflammatory drugs (NSAIDs)"

Abstract Number: 0540 • ACR Convergence 2024
Nonsteroidal Anti-Inflammatory Drug Use and Incident Hypertension Among Patients with Axial Spondyloarthritis
Jose Meade Aguilar¹, Jean Liew², Rachael Stovall³, Sofia Ramiro⁴ and Lianne S Gensler⁵, ¹Boston Medical Center, Boston, MA, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³University of Washington, Seattle, ⁴Leiden University Medical Center, Bunde, Netherlands, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Patients with axial spondyloarthritis (axSpA) have a heightened risk of cardiovascular morbidity and mortality. Nonsteroidal anti-inflammatory drugs (NSAIDs) are first line treatment for axSpA,…
Abstract Number: 1446 • ACR Convergence 2024
Is the Remission Achieved with Asdas, Basdaı a Real Remission? Should Ultrasound Be Added to the Parameters?
Emrah Koç¹, Burak Okyar², Sibel Bakırcı³, suade Özlem Badak², Ali Nail Demir⁴, İsmail Uçar⁴, Gökhan Sargın⁵, Servet Yüce⁶ and Emine Duygu Ersözlü¹, ¹Adana City Training and Research Hospital, Adana, Turkey, ²Adana City Training and Research Hospital, Adana, ³Antalya training and research hospital, Antalya, Turkey, ⁴Mersin City Hospital, Mersin, Turkey, ⁵Aydin Adnan Menderes University, Aydın, Turkey, ⁶Şırnak Provincial Health Directorate Public Health Department, Şırnak, Turkey
Background/Purpose: The study aimed to evaluate changes in enthesis areas in ankylosing spondylitis patients in remission for at least six months, using either NSAIDs or…
Abstract Number: 1476 • ACR Convergence 2024
Individualizing NSAIDs in Axial Spondyloarthritis Through a Series of N-of-1 Clinical Trials with Bayesian Analysis
Mark Hwang¹, Seokhun Kim², Shervin Assassi³, Joyce Samuel⁴, Charles Green², Jon Tyson⁴ and John Reveille⁵, ¹Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine, UTHealth Houston, Houston, TX, ²UTHealth Houston, Houston, ³UTHealth Houston Division of Rheumatology, Houston, TX, ⁴UTHealth Houston, Houston, TX, ⁵UTHealth Houston Division of Rheumatology, Houston
Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are first line pharmacological treatment for Axial Spondyloarthritis (axSpA), yet individual responses to different NSAIDs vary significantly. This study aims…
Abstract Number: 2091 • ACR Convergence 2024
Changes in Analgesic Prescriptions for the Treatment of Osteoarthritis During the COVID-19 Pandemic
Derek Ochi¹, Dagoberto Pina², Manmeet Kaur³, Jeffery Fine⁴, Daniel Black⁵ and Barton Wise⁶, ¹Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis, Sacramento, CA, ²School of Medicine, University of California Davis, Sacramento, CA, ³Division of Rheumatology, Allergy and Immunology, University of California San Diego, San Diego, CA, ⁴Department of Public Health Sciences, University of California Davis, Sacramento, CA, ⁵Innovation Technology - Data Center of Excellence, University of California Davis, Sacramento, CA, ⁶Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis and Department of Orthopaedic Surgery, University of California Davis, Sacramneto, CA
Background/Purpose: Osteoarthritis (OA) is a leading cause of disability. The 2019 American College of Rheumatology (ACR)/Arthritis Foundation (AF) Guideline for the Management of OA recommends…
Abstract Number: 2317 • ACR Convergence 2024
Chronic Kidney Disease in Patients with Psoriatic Arthritis: A Cohort Study
Fadi Kharouf¹, Shangyi Gao², Shahad Al-Matar³, Daniel Pereira⁴, Richard Cook⁵, Vinod Chandran⁶ and Dafna Gladman⁷, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Toronto, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Waterloo, Waterloo, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Chronic kidney disease (CKD) is a comorbidity in psoriatic arthritis (PsA). In this study, we aimed to define the prevalence of CKD in patients…
Abstract Number: 2343 • ACR Convergence 2024
Temporal Trends in and Associations with NSAID Prescription in Adult and Pediatric Patients with IBD
Adam Mayer¹, Rui Xiao², Andrew Grossman³, Meenakshi Bewtra⁴, Michael George² and Pamela Weiss⁵, ¹University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the management of musculoskeletal symptoms in patients with inflammatory bowel disease (IBD) and IBD-associated arthritis remains…
Abstract Number: 2346 • ACR Convergence 2024
Treatment Effect on Predictors of Ankylosis in Axial Spondyloarthritis
Pauline KRUG¹, Anthony Lichaa¹ and Adrien Nzeusseu Toukap², ¹Cliniques universitaires St-Luc, Brussel, Belgium, ²Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Axial spondyloarthritis (axSpA) is a progressive chronic inflammatory disease. In its early stages, symptoms appear without radiographic evidence. Later, structural lesions are observed on…
Abstract Number: 0533 • ACR Convergence 2023
Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and b/tsDMARDs in Daily Practice?
Francesco Natalucci¹, Pauline KRUG², Angela DE SOUSA LEITE², Tatiana Sokolova³, Patrick Durez⁴, Maria S. Stoenoiu² and Adrien NZEUSSEU TOUKAP⁵, ¹UCLouvain University, Sermoneta, Italy, ²Cliniques Universitaires Saint-Luc, Brussels, Belgium, ³Université Catholique de Louvain, Brussels, Belgium, ⁴UCLouvain, Brussels, Belgium, ⁵Cliniques universitaires Saint-Luc, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Randomized-controlled trials (RCTs) done in axial spondyloarthritis (axSpA) patients have shown that remission in axSpA (including nonradiographic axSpA) patients treated without b/tsDMARDs (TNFα blockers,…
Abstract Number: 1196 • ACR Convergence 2023
Association of Long-Term Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with Worsening Symptoms and Structural Changes of Knee Osteoarthritis: An Individual Patient Data Meta-Analysis of Cohort Studies
Zubeyir Salis¹ and Amanda Sainsbury², ¹The University of New South Wales, Kensington, Australia, ²The University of Western Australia, Crawley, Australia
Background/Purpose: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are commonly prescribed for short-term management of symptoms of knee osteoarthritis (KOA), but they are often used long-term, and the…
Abstract Number: 1394 • ACR Convergence 2023
Comorbidities, Not Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs, May Be Associated with Chronic Kidney Disease in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Study
Bon San Koo¹, Subin Hwang¹, Ye-Jee Kim², Soo Min Ahn² and Wook Jang Seo³, ¹Inje University Seoul Paik Hospital, Seoul, South Korea, ²Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ³Department of Rheumatology, Veteran Health Service Medical Center, Seoul, South Korea
Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed as first-line treatment for symptom relief and inflammation reduction in patients with ankylosing spondylitis (AS). However, long-term…
Abstract Number: 2053 • ACR Convergence 2023
Predictive Factors Associated with Treatment Response in Chronic Nonbacterial Osteomyelitis
Katherine Nowicki¹, Nathan Rogers², Carson Keeter², Nathan Donaldson², Jennifer Soep² and Yongdong (Dan) Zhao³, ¹University of Colorado, Lakewood, CO, ²University of Colorado, Aurora, CO, ³University of Washington, Redmond, WA
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is characterized by sterile inflammatory bone lesions and most commonly affects skeletally immature children. Non-steroidal anti-inflammatory drugs (NSAIDs) are the…
Abstract Number: 2565 • ACR Convergence 2023
The Problem of Pain in Rheumatology: A Population-based Study of Annual Trends in Pain Management Modalities in Patients with Autoimmune Rheumatic Diseases in the United States, 2007-2021
Titilola Falasinnu¹, Di Lu² and Matthew Baker³, ¹Stanford School of Medicine, Palo Alto, CA, ²Stanford School of Medicine, Stanford, CA, ³Stanford University, Menlo Park, CA
Background/Purpose: Autoimmune rheumatic diseases (ARD) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are salient causes of disability, functional limitations, reduced quality of…
Abstract Number: 0374 • ACR Convergence 2023
Actionable Adverse Events in a Real-Practice Cohort of Children with Juvenile Idiopathic Arthritis. Results from the CAPRI Registry
Bashayer Alnuaimi¹, Michelle Batthish², Roberta A Berard³, Gilles Boire⁴, Sarah Campillo¹, Amieleena Chhabra⁵, Julie Couture⁶, Paul Dancey⁷, Brian Feldman⁸, Tommy Gerschman⁹, Julie Herrington¹⁰, Kristin Houghton¹¹, Adam Huber¹², Claire LeBlanc¹, Lillian Lim¹³, Jean-Philippe Proulx-Gauthier⁶, Heinrike Schmeling¹⁴, Rosie Scuccimarri¹, Lori Tucker¹⁵, Jaime Guzman¹⁵, Gaëlle Chédeville¹ and For The CAPRI Registry Investigators¹⁶, ¹McGill University Health Center, Montreal, QC, Canada, ²McMaster Children's Hospital, Hamilton, ON, Canada, ³Children's Hospital - London Health Sciences Centre, London, ON, Canada, ⁴Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵British Columbia Hospital, Vancouver, BC, Canada, ⁶CHU de Quebec- Universite Laval, Quebec City, QC, Canada, ⁷Memorial University of Newfoundland, St. John's, NL, Canada, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹British Columbia Children's Hospital, Burnaby, BC, Canada, ¹⁰McMaster University, Hamilton, ON, Canada, ¹¹British Columbia University, Vancouver, BC, Canada, ¹²IWK Health Centre, Halifax, NS, Canada, ¹³University of Alberta, Edmonton, AB, Canada, ¹⁴University of Calgary, Calgary, AB, Canada, ¹⁵British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁶CAPRI, Montreal, QC, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic disease of childhood and most children require long-term treatment. Adverse events (AE) during…
Abstract Number: 048 • 2023 Pediatric Rheumatology Symposium
Comparative Efficacy and Safety of Ibuprofen and Naproxen in the Treatment of Oligoarticular Juvenile Idiopathic Arthritis (oJIA): Bi-national Cohort Study
Orly Ohana¹, Itay Marmor², Liora Harel³, Shiri Rubin⁴, rotem tal⁵, Yoel Levinsky⁶, Orit Peled⁷ and Gil Amarilyo³, ¹Pediatric C ward, Schneider Children's Medical Centre, Petach Tikva, Israel, ²Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ³Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel, ⁴Pediatric Ear Nose and Throat Unit Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁵Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁶Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ⁷Department of Pharmacy, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
Background/Purpose: JIA is the most common childhood rheumatic disease. NSAIDs and intraarticular corticosteroid injections (IACI) are first-line therapy for oJIA. NSAIDs Adverse events (AEs) include…
Abstract Number: 0073 • ACR Convergence 2022
Opioid and Pain Medication Prescribing by Rheumatologists for Medicare Part D Beneficiaries from 2013 to 2019
Erin Valley¹, Connor Pedersen¹, Kathryn Henry², Ali Duarte-Garcia³, Viktoriya Sabchyshyn¹ and Mike Putman⁴, ¹Medical College of Wisconsin, Milwaukee, WI, ²Medical College of Wisconsin, Manitowoc, WI, ³Mayo Clinic, Rochester, MN, ⁴The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Prescription opioid medications are highly effective in managing acute pain, but their use for chronic pain remains controversial. The objective of this study is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].